Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Glutapak R
- Development stage
- Unknown
- Lead developer
- Megalabs
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral, Enteral
01
Overview
Glutapak R is a specialized enteral nutrition supplement developed and marketed by Megalabs. It is a combination product consisting of 10 grams of L-glutamine and 100 million CFU of the probiotic Lactobacillus reuteri strain DSM 17.938. L-glutamine serves as a vital energy source for enterocytes, supporting the repair and maintenance of the intestinal mucosal barrier. Lactobacillus reuteri helps restore the balance of the gut microbiota and may modulate the intestinal immune response. The product is indicated for the dietary management of various gastrointestinal conditions, including diarrhea, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and gastrointestinal side effects associated with chemotherapy and radiotherapy. It is supplied as an unflavored powder for oral or enteral administration via feeding tubes.
- Brand names
- Glutapak R
Beyond the preview
Go deeper on Glutapak R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glutapak R.